News

Medigene participates at six national and international conferences

Martinsried/Munich, 4 November 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at six upcoming scientific, investor and business development conferences:

  • BioEurope

Date: 7 - 9 November 2016
Location: Cologne, Germany

  • SITC 2016 - Society for Immunotherapy of Cancer

            Date: 9 - 13 November 2016
            Location: National Harbor, Maryland, USA
             

  • Neoantigens Summit

            Date: 15 - 17 November 2016
            Location: Boston, USA
            Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk on the topic: "Are we Limited to Treatment of Tumors with High-Mutational Loads and Patients with Pre-Existing Neoantigen-Specific T Cells?"

  • 6th Munich Biomarker Conference

            Date: 29 - 30 November 2016
            Location: Munich, Germany
            Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a keynote talk on the topic: "From personalized to individualized medicine, the next major step in developing the medicine of the future".

  • EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

            Date: 29 November - 2 December 2016
            Location: Munich, Germany

  • ASH 2016 - The 58th American Society of Hematology Annual Meeting

            Date: 3 - 6 December 2016
            Location: San Diego, USA

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.